An ultrasound-based treatment for prostate cancer showed better safety and operative metrics versus robotic radical ...

TULSA reduces tumor volume and PSA levels, improving urinary and sexual function in prostate cancer patients. Five-year TACT study data shows 80% of patients had no significant disease after one year, ...

It’s the second most common type of cancer among men and affects 1 in every 8 men in the United States. September is Prostate Cancer Awareness Month, and the American Cancer Society says this type of ...

A multicenter clinical study in Austria has shown that a new, highly precise ultrasound approach can successfully target and treat early prostate cancer while preserving patients' quality of life.

A new imaging approach developed by researchers at Heriot-Watt University has shown "extremely encouraging" results in early-stage clinical trials on prostate cancer at the Western General Hospital in ...

Evaluating the spectrum of disease within Gleason grade group 3: Results from a large institutional cohort. This is an ASCO Meeting Abstract from the 2025 ASCO Genitourinary Cancers Symposium. This ...

As a result, researchers have explored less invasive options that aim to treat the cancer while preserving quality of life. One such approach is TULSA, which uses real-time MRI guidance to deliver ...

The 2026 European Association of Urology (EAU) annual meeting featured a PARP inhibitors for prostate cancer session and a presentation by Dr. Martin Gleave discussing how to optimize tissue biopsy ...